Who are Gallium-68-tilmanocept's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): strontium-89, Dexamethasone plus Radium-223, Ga-68-DOTATOC, [F-18]-Fludeoxyglucose, Fludeoxyglucose F 18 (FDG), PET Scan with [18F] VAT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gallium-68-tilmanocept.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Gallium-68-tilmanocept — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gallium-68-tilmanocept (Gallium-68-tilmanocept) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiopharmaceutical; PET imaging agent. Area: Oncology; Infectious Disease; Inflammation Imaging.

phase 3 Radiopharmaceutical; PET imaging agent Mannose receptor (CD206) Oncology; Infectious Disease; Inflammation Imaging Small molecule Live · refreshed every 30 min

Target snapshot

Gallium-68-tilmanocept (Gallium-68-tilmanocept) — UMC Utrecht. Gallium-68-tilmanocept is a radioactive imaging agent that binds to mannose receptors on immune cells to visualize inflammation and infection sites.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Gallium-68-tilmanocept TARGET	Gallium-68-tilmanocept	UMC Utrecht	phase 3	Radiopharmaceutical; PET imaging agent	Mannose receptor (CD206)
strontium-89	strontium-89	Alberta Health services	marketed	Radiopharmaceutical; bone-seeking radioisotope	Hydroxyapatite in bone matrix; osteoblast uptake
Dexamethasone plus Radium-223	Dexamethasone plus Radium-223	University Health Network, Toronto	marketed	Combination therapy: corticosteroid plus alpha-emitting radiopharmaceutical	Radium-223 targets calcium-mimetic bone uptake; dexamethasone targets glucocorticoid receptor
Ga-68-DOTATOC	Ga-68-DOTATOC	Weill Medical College of Cornell University	marketed	Radiopharmaceutical	Somatostatin receptors (SSTRs) on neuroendocrine tumor cells
[F-18]-Fludeoxyglucose	[F-18]-Fludeoxyglucose	University of Saskatchewan	marketed	Radiopharmaceutical; PET imaging agent	Glucose transporter (GLUT1); hexokinase
Fludeoxyglucose F 18 (FDG)	Fludeoxyglucose F 18 (FDG)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Radiopharmaceutical; PET imaging agent	Glucose transporter (GLUT1); hexokinase
PET Scan with [18F] VAT	PET Scan with [18F] VAT	Stony Brook University	marketed	PET imaging agent / Radiopharmaceutical	Vascular adhesion molecules (VAM)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiopharmaceutical; PET imaging agent class)

Clarity Pharmaceuticals Ltd · 1 drug in this class
Radiomedix, Inc. · 1 drug in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class
UMC Utrecht · 1 drug in this class
University of Colorado, Denver · 1 drug in this class
University of Saskatchewan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gallium-68-tilmanocept — Competitive Intelligence Brief. https://druglandscape.com/ci/gallium-68-tilmanocept. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab